Amneal Pharmaceuticals, Inc. (AMRX)

5.90 -0.15 (-2.48%) At close: 04:00PM EDT

Amneal Pharmaceuticals, Inc.

400 Crossing Boulevard
3rd Floor
Bridgewater, NJ 08807
United States
908 947 3120
https://amneal.com

Sector(s): Healthcare
Industry: Drug Manufacturers - Specialty & Generic
Full-time employees: 7,850

Key executives

Name	Title	Pay	Exercised	Year born
Mr. Chirag K. Patel	Co-Founder, Co-CEO, President & Director	1.71M	N/A	1967
Mr. Chintu Patel R.Ph.	Co-Founder, Co-CEO & Director	1.7M	N/A	1972
Mr. Anastasios G. Konidaris	Executive VP & CFO	1.04M	N/A	1967
Mr. Jason B. Daly Esq.	Senior VP, Chief Legal Officer & Corporate Secretary	779.06k	N/A	1974
Ms. Nikita Shah	Executive VP & Chief Human Resources Officer	848.83k	N/A	1979
Mr. Andrew S. Boyer	Executive VP & Chief Commercial Officer of Generics	1.2M	N/A	1966
Mr. Anthony DiMeo	Head of Investor Relations	N/A	N/A	N/A
Mr. Gregory Sgammato	Senior Vice President of Corporate Development	N/A	N/A	N/A
Mr. Pranav Mehta	Senior VP of Strategic Sourcing & Supply Management	N/A	N/A	N/A
Dr. Sanjay Kumar Jain Ph.D.	Chief Quality Officer	N/A	N/A	N/A

Amounts are as of 31 December 2023, and compensation values are for the last fiscal year ending on that date. Pay includes salary, bonuses, etc. Exercised is the value of options exercised during the fiscal year. Currency in USD.

Description

Amneal Pharmaceuticals, Inc., together with its subsidiaries, develops, manufactures, markets, and distributes generics, injectables, biosimilars, and specialty branded pharmaceutical products worldwide. The company operates through three segments: Generics, Specialty, and AvKARE. The Generics segment offers immediate and extended release oral solid, powder, liquid, sterile injectable, nasal spray, inhalation and respiratory, biosimilar, ophthalmic, film, transdermal patch, and topical products. The Specialty segment develops, promotes, sells, and distributes pharmaceutical products with focus on central nervous system disorders, including Parkinson's disease, and endocrine disorders. This segment also provides Rytary, an oral capsule formulation of carbidopa-levodopa to treat Parkinson's disease, post-encephalitic parkinsonism, and parkinsonism; Unithroid for the treatment of hypothyroidism; and IPX203, a pipeline product for Parkinson's disease. The AvKARE segment offers pharmaceuticals, medical and surgical products, and services primarily to governmental agencies, the Department of Defense, and the Department of Veterans Affairs. This segment also distributes bottle and unit dose pharmaceuticals under the AvKARE and AvPAK names; and packages and distributes pharmaceuticals and vitamins to its retail and institutional customers. It sells its products through wholesalers, distributors, hospitals, chain pharmacies, and individual pharmacies. The company was formerly known as Atlas Holdings, Inc. and changed its name to Amneal Pharmaceuticals, Inc. in 2018. Amneal Pharmaceuticals, Inc. was founded in 2002 and is headquartered in Bridgewater, New Jersey.

Corporate governance

Amneal Pharmaceuticals, Inc.’s ISS governance QualityScore as of 1 April 2024 is 3. The pillar scores are Audit: 2; Board: 6; Shareholder rights: 4; Compensation: 3.

Corporate governance scores courtesy of Institutional Shareholder Services (ISS). Scores indicate decile rank relative to index or region. A decile score of 1 indicates lower governance risk, while 10 indicates higher governance risk.